The Relative Strength (RS) Rating for Dynavax Technologies moved into a new percentile Monday, as it got a lift from 69 to 73.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the market's biggest winners often have an RS Rating north of 80 as they launch their largest runs. See if Dynavax Technologies can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
While the stock is not near an ideal buying range right now, see if it is able to form and break out from a proper base.
The company reported 20% earnings growth in its most recent report, while sales growth came in at 16%. Keep an eye out for the company's next round of numbers on or around Feb. 20.
Dynavax Technologies earns the No. 33 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
